Table 1

Changes in insulin dose, mean BG, HbA1c, and stimulated C-peptide in type 1 diabetic patients with (C-peptide positive) and without (C-peptide negative) residual β-cell function before (week 0) and during (week 4) 4 weeks of treatment with liraglutide or insulin alone

TreatmentC-peptide positiveC-peptide negativeC-peptide negative
Liraglutide + insulinLiraglutide + insulinInsulin only
Week 0Week 4Week 0Week 4Week 0Week 4
Insulin dose (units/kg per day)0.50 ± 0.060.31 ± 0.08*0.72 ± 0.080.59 ± 0.060.62 ± 0.040.64 ± 0.05 (NS)
Mean blood glucose (mmol/L)6.0 ± 0.26.3 ± 0.3 (NS)7.5 ± 0.47.7 ± 0.4 (NS)7.5 ± 0.47.5 ± 0.6 (NS)
HbA1c (%)6.6 ± 0.36.4 ± 0.27.5 ± 0.27.0 ± 0.17.1 ± 0.36.9 ± 0.2 (NS)
C-peptide (pmol/L)520 ± 106457 ± 79 (NS)
  • Data are means ± SE. Mean blood glucose levels are derived from continuous glucose monitoring as mean values during 3 days with identical food intake and physical activity in week 0 and week 4. NS, nonsignificant vs. week 0 in the same group.

  • *P < 0.001 and

  • P < 0.05 vs. week 0 in the same group.

  • n = 8.